Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

Published On 2022-02-25 04:30 GMT | Update On 2022-02-25 04:30 GMT

Hyderabad: Amid the military offensive by Russia against Ukraine, Indian pharma exporters are in wait and watch mode on dispatching fresh orders to them and some of the CIS countries, industry sources said on Thursday.

India exported over USD 181 million worth of pharmaceutical goods to Ukraine in FY 21, nearly 44 per cent growth over the previous year, while Russia contributed nearly USD 591 million last fiscal with a growth of 6.95 per cent compared to a year before, according to Pharmaceuticals Export Promotion Council of India (Pharmexcil), body under the Department of Commerce.

An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority.

"We have had a strong presence in the region for over three decades. Ensuring the well-being of our staff is the first and foremost priority, along with meeting patient needs and business continuity. We have been monitoring developments closely and preparing accordingly, and continue to do so," a spokesperson of the company told the agency.

A senior official of a pharma company based out of the city said they currently have orders on hand to be dispatched to some of the CIS countries following the developments between Russia and Ukraine.

"As of now there are no restrictions on pharma exports to any these countries. However, we want to wait for some time to get more clarity on how the situation will turn out. Ultimately our payments from those countries should not be affected as result of war," the official said on condition of anonymity.

When contacted, Udaya Bhaskar, Director General of Pharmexcil said the pharma body has neither received any communication from the Centre on export nor from drug makers on the state of affairs.

Read Also - Dr Reddys warns against bogus Sputnik V suppliers in India

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

Similar News

Bayer Canada partners with Mint Pharma for distribution of ADALAT XL 30 mg tablets in Canada

AstraZeneca Koselugo recommended for approval in EU for plexiform neurofibromas in adults with neurofibromatosis type 1

AbbVie submits new drug application to USFDA for Tavapadon for Parkinsons disease

Patna Shocker: Pharma Representative Brutally Murdered, Probe Underway

Delhi ITAT Deletes Rs 14.98 Cr Ad-Hoc Disallowance on Mankind Pharma's Travel Expenses

Delhi Govt Bans Genetic Sample Transfers, Tightens Abortion Pill Sales to Curb Sex-Selective Practices

CDSCO Panel Recommends Updating Prescribing Information for Sanofi's Vaccine

Eli Lilly Kisunla gets marketing authorization from European Commission for early symptomatic Alzheimer's disease